Article
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jul 2011
Guo Jun, Si Lu, Kong Yan, Flaherty Keith T, Xu Xiaowei, Zhu Yanyan, Corless Christopher L, Li Li, Li Haifu, Sheng Xinan, Cui Chuanliang, Chi Zhihong, Li Siming, Han Mei, Mao Lili, Lin Xuede, Du Nan, Zhang Xiaoshi, Li Junling, Wang Baocheng, Qin Shukui
Abstract excerpt
PURPOSE: Melanomas harbor aberrations in the c-Kit gene. We tested the efficiency of the tyrosine kinase inhibitor imatinib in selected patients with metastatic melanoma harboring c-Kit mutations or amplifications. PATIENTS AND METHODS: Forty-three patients with metastatic melanoma harboring c-Kit aberrations were enrolled on this phase II trial. Each patient received a continuous dose of imatinib 400 mg/d unless...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.